John Cumming Net Worth

The estimated Net Worth of John W Cumming is at least $6.19 Million dollars as of 15 September 2023. Mr. Cumming owns over 2,600 units of T2 Biosystems Inc stock worth over $12,089 and over the last 20 years he sold TTOO stock worth over $6,059,417. In addition, he makes $122,813 as Lead Independent Director at T2 Biosystems Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Cumming TTOO stock SEC Form 4 insiders trading

John has made over 19 trades of the T2 Biosystems Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 2,600 units of TTOO stock worth $5,980 on 15 September 2023.

The largest trade he's ever made was exercising 467,500 units of T2 Biosystems Inc stock on 2 February 2007 worth over $2,618,000. On average, John trades about 34,103 units every 147 days since 2004. As of 15 September 2023 he still owns at least 5,256 units of T2 Biosystems Inc stock.

You can see the complete history of Mr. Cumming stock trades at the bottom of the page.

John Cumming biography

John W. Cumming serves as Lead Independent Director of the Company. He has served as a member of our Board of Directors since July 2014 and also serves as a member of the Board of Directors of TransMed7, LLC. Mr. Cumming currently serves as Chief Executive Officer and Managing Director of Cumming & Associates LLC, a strategic advisory firm serving the healthcare industry. From August 2000 until December 2013, Mr. Cumming served in a number of leadership roles at Hologic Inc., a diagnostics company, including as Chief Executive Officer from 2001 through 2009 and again from July 2013 through December 2013, as President from 2001 until 2003, as Chairman of the Board from 2002 until 2007 and again from 2008 through 2011, and as Global Strategic Advisor from 2011 through July 2013. Mr. Cumming attended the University of South Carolina. Mr. Cumming’s extensive knowledge of and experience with diagnostic product companies and expertise as a strategic advisor focused on the healthcare industry contributed to our Board of Directors’ conclusion that he should serve as a director of our company.

What is the salary of John Cumming?

As the Lead Independent Director of T2 Biosystems Inc, the total compensation of John Cumming at T2 Biosystems Inc is $122,813. There are 7 executives at T2 Biosystems Inc getting paid more, with John McDonough having the highest compensation of $1,637,480.

How old is John Cumming?

John Cumming is 74, he's been the Lead Independent Director of T2 Biosystems Inc since 2020. There are no older and 18 younger executives at T2 Biosystems Inc.

What's John Cumming's mailing address?

John's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.

Insiders trading at T2 Biosystems Inc

Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ..., and Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.

What does T2 Biosystems Inc do?

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www

Complete history of Mr. Cumming stock trades at Hologic and T2 Biosystems Inc

T2 Biosystems Inc executives and stock owners

T2 Biosystems Inc executives and other stock owners filed with the SEC include:

• John McDonough,
  Non-Executive Chairman of the Board
• Alec Barclay,
  Chief Operating Officer
• John J. Sperzel III, B.Sc.,
  Chairman & CEO
• Thomas Lowery,
  Chief Scientific Officer
• Alec J. Barclay,
  Chief Operations Officer
• Seymour Liebman,
  Director
• David Elsbree,
  Independent Director
• John Cumming,
  Lead Independent Director
• Philip Taylor,
  IR Contact Officer
• Robin Toft,
  Independent Director
• Ninfa Saunders,
  Independent Director
• Thierry Bernard,
  Independent Director
• Anthony Pare,
  Chief Commercial Officer
• Michael Gibbs,
  Vice President, General Counsel
• John Sprague,
  Chief Financial Officer
• John Sperzel,
  President, Chief Executive Officer, Director
• Brett A. Giffin,
  Chief Commercial Officer
• Dr. Aparna Jha Ahuja M.D.,
  Chief Medical Officer
• Kelley J. Morgan,
  Chief People Officer
• Michael Terrence Gibbs,
  VP & Gen. Counsel
• John M. Sprague CPA,
  Chief Financial Officer
• Aparna Ahuja,
  Chief Medical Officer
• Brett A. Giffin,
  Chief Commercial Officer
• Joanne Spadoro,
  Chief Operations Officer
• Stanley Lapidus,
  Director
• Rahul Dhanda,
  SVP of Corporate Development
• Sachs Group Incgoldman Sach...,
  
• Shawn Lynch,
  Chief Financial Officer
• Joshua H. Bilenker,
  Director
• David Harding,
  Chief Commercial Officer
• Michael J. Cima,
  Director
• Harry W Wilcox,
  Director
• Group L.P.Crg Partners Iii ...,
  
• Darlene M Deptula Hicks,
  Chief Financial Officer
• Stanley N Lapidus,
  Director
• Thomas J. Carella,
  
• Michael A. Pfaller,
  Chief Medical Officer
• Venture Partners V, L.P.Pol...,
  
• Sarah O. Kalil,
  Chief Operating Officer
• Maurice L Castonguay,
  Chief Financial Officer
• Advisors, L.L.C. Mbd,
  
• Venture Partners V, L.P.Pol...,
  
• Sachs Group Incgoldman Sach...,
  
• Alan L Crane,
  Director
• Ventures Fund 2004 L P Flag...,
  
• Capital Iii Lp Aisling Capi...,
  
• Laura Lee Adams,
  
• Adrian M Jones,
  Director
• Sachs & Co. Llcgoldman Sach...,
  
• Group L.P.Crg Partners Iii ...,